iiinova — where your digital self keeps evolving

Reposted by Mattia Cordioli

Nightingale Health @nightingalehealth.com · 03/12/2024

Are you attending the UK Biobank Scientific Conference on December 10? Our Founder & Scientific Advisor, Peter Würtz, and Head of Global Medical Research Business, Helena Sundberg, will be at the event and would love to connect with you! Book a meeting to talk more: research@nightingalehealth.com

022

Mattia Cordioli @bordinki.bsky.social · 10/10/2023

A huge THANK YOU to my supervisor @andganna.bsky.social and all other coauthors who have been fundamental to get all this work done!

010

Mattia Cordioli @bordinki.bsky.social · 10/10/2023

Take-home message 2: The robust associations with some of the socio-demographic factors considered suggest that socio-economically disadvantaged groups would benefit from targeted interventions to improve the dispensing and uptake of pharmacological treatments. (13/n)

100

Mattia Cordioli @bordinki.bsky.social · 10/10/2023

Take-home message 1: Our results suggest a very limited role of genetics, including established pharmacogenes, on persistence and adherence. (12/n)

100

Mattia Cordioli @bordinki.bsky.social · 10/10/2023

Moreover, we tested whether the GWAS results from FinnGen could be used to build a polygenic score for statin adherence and found this was significantly associated with observed adherence. (11/n)

100

Mattia Cordioli @bordinki.bsky.social · 10/10/2023

We finally replicated the results for statins in Estonian Biobank, which have similar drug purchase and genetic data, and observed consistent effects for health and socio-economic factors present in both studies. (10/n)

100

Mattia Cordioli @bordinki.bsky.social · 10/10/2023

We also wondered how ploygenic scores for the traits above would predict persistence and adherence. Effect sizes were overall smaller than those for the health and socio-demographic factors at the beginning, and could explain a lower fraction of variance in adherence. (9/n)

100

Mattia Cordioli @bordinki.bsky.social · 10/10/2023

Interestingly, adherence to statins and BP medications were positively correlated with participating in one or more of the optional questionnaires of UK Biobank. (8/n)

100

Mattia Cordioli @bordinki.bsky.social · 10/10/2023

We ran a GWAS of persistence and adherence to each medication. We didn’t find significant associations with either phenotype but could use the results to explore the genetic overlap between persistence, adherence and other health and behavioral traits. (7/n)

100

Mattia Cordioli @bordinki.bsky.social · 10/10/2023

None of the pharmacogenes we tested showed an effect on adherence. (6/n)

100

Mattia Cordioli @bordinki.bsky.social · 10/10/2023

We then turned to genetics, the first suspect being relevant and well established pharmacogenes. CYP2C9 intermediate met. (higher risk of fluvastatins side effects) associated with lower odds of persistence. Similar for tamoxifen and CYP2D6 poor met. (lower drug response). (5/n)

100

Mattia Cordioli @bordinki.bsky.social · 10/10/2023

We first considered the effect 8 health and sociodemographic factors. Non-Finnish/Swedish mother tongue (proxy for recent immigration) and receiving social assistance benefits (lower socio-economic status) showed the biggest effects on both phenotypes, across all meds. (4/n)

100

Mattia Cordioli @bordinki.bsky.social · 10/10/2023

We looked at these phenotypes across 5 relevant med classes, including up to N=1 814 591. We explored health and socio-demographic factors in the nation-wide Finregistry data, and genetics for the subset of ppl from FinnGen. We replicated our results in Estonian Biobank. (3/n)

100

Mattia Cordioli @bordinki.bsky.social · 10/10/2023

Based on data from all prescription drug purchases made in Finland from 1998 to 2020, we defined two drug taking behaviors: continuing the treatment for at least one year vs early discontinuing it (persistence), and following the prescribed therapeutic regimen (adherence) (2/n)

100

Mattia Cordioli @bordinki.bsky.social · 10/10/2023

Let's inaugurate this profile by sharing a new preprint, the main project I have been working on during my PhD! Why are people not adherent to their? How much do social vs genetic factors impact that? What about relevant pharmacogenes? Here’s what we found! (1/n) www.medrxiv.org/content/10.1...

medrxiv.org

Socio-demographic and genetic risk factors for drug adherence and persistence: a retrospective natio...

medRxiv - The Preprint Server for Health Sciences

153